Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery
NCT01545700
Completed
The question of a possible hyperglycemic effect from single-dose dexamethasone is an important issue for clinicians managing patients in the intraoperative and postoperative periods. Recent evidence suggests that even moderate elevations in blood glucose levels may be associated with adverse events. The aim of this clinical investigation is to determine whether standard clinical doses of dexamethasone produce hyperglycemia in the perioperative period.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
09/12/2019
Locations: NorthShore University HealthSystem, Evanston, Illinois
Conditions: Postoperative Complications
Register for Updates
Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
NCT01471054
Terminated
To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex) and compare it with safety and efficacy of intravitreal bevacizumab in eyes with macular edema after plaque radiotherapy of uveal melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2019
Locations: Ocular Oncology Service, Wills Eye Institute, Philadelphia, Pennsylvania
Conditions: Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Register for Updates
A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
NCT02518113
Completed
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/28/2019
Locations: City of Hope National Medical Center, Duarte, California +21 locations
Conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
Register for Updates
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT02224729
Completed
This phase II trial studies side effects and how well bendamustine hydrochloride, bortezomib, and dexamethasone work in treating patients with newly diagnosed multiple myeloma. Drugs used in chemotherapy, such as bendamustine hydrochloride and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2019
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Register for Updates
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
NCT03785184
Withdrawn
This study will evaluate the safety and preliminary efficacy of venetoclax when combined with lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14) positive multiple myeloma (MM). This study will consist of 2 parts: Part 1 Dose Escalation and Part 2 Dose Expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2019
Locations: City of Hope /ID# 212211, Duarte, California +21 locations
Conditions: Multiple Myeloma
Register for Updates
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
NCT00137995
Completed
The primary objective of this study is to evaluate the efficacy and safety of induction therapy R-ICE in comparison to R-DHAP after 3 cycles adjusted to successful mobilization of stem cells in patients with previously treated diffuse large B-cell lymphoma CD20. The goal is to detect a difference in mobilization adjusted response rate of 15% between R-ICE and R-DHAP. The other objective is to evaluate the efficacy and safety of MabThera maintenance therapy after transplantation as measured by... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/22/2019
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +9 locations
Conditions: Lymphoma, Large-Cell, Diffuse
Register for Updates
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00687674
Terminated
RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Sorafenib and lenalidomide may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving so... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/12/2019
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
NCT02520115
Completed
This pilot research trial studies folate receptor in diagnosing ovarian cancer using serum samples from patients with a newly diagnosed pelvic mass or previously diagnosed ovarian cancer. Studying samples of serum from patients with ovarian cancer in the laboratory may help understand the use of folate receptor induction as a clinical tool in initial diagnosis, surveillance, and recurrence.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/12/2019
Locations: Karmanos Cancer Institute at McLaren Bay Region, Bay City, Bay City, Michigan +1 locations
Conditions: Adnexal Mass, Borderline Ovarian Epithelial Tumor, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor, Ovarian Neoplasm, Ovarian Serous Tumor, Recurrent Ovarian Carcinoma
Register for Updates
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
NCT03657420
Withdrawn
This research study is studying a combination of drugs as a possible treatment for multiple myeloma. The drugs that will be administered are: * ABI-009 (nab-rapamycin) * Pomalidomide * Dexamethasone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2019
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
The Adrenal Contribution to Androgen Production in Girls During Puberty
NCT01062568
Completed
In girls with elevated androgens the precise source of androgen excess throughout puberty and early adolescence has not been carefully examined. The investigators propose to examine whether the adrenal gland produces the majority of androgens during puberty by studying the differences in androgen responses to adrenocorticotropin hormone (ACTH) administration in normal weight (NW) and obese (OB) girls ages 7-18. The investigators' analyses will compare steroid changes before and 60 min after ACTH... Read More
Gender:
FEMALE
Ages:
Between 7 years and 18 years
Trial Updated:
08/08/2019
Locations: University of california, san diego, La Jolla, California
Conditions: Development
Register for Updates
Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT01363817
Completed
The purpose of this study is to identify a safe and tolerable dose of BMS-906024, either alone or in combination with Dexamethasone in subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma who no longer respond to or have relapsed from standard therapies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2019
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +5 locations
Conditions: Lymphoblastic Leukemia, Acute T-cell, Precursor T-Cell Lymphoblastic Lymphoma
Register for Updates
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
NCT02648490
Completed
This study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of humanized anti-EGFR monoclonal antibody, HLX07, in patients with epithelial cancer who have failed standard therapy and deemed unamenable by conventional therapy. This study will also evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of HLX07 and explore the potential prognostic and predictive biomarkers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2019
Locations: Henlix, Inc., Fremont, California +1 locations
Conditions: Solid Tumour
Register for Updates